Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- ActHIB to Reach Japanese Market in December?
October 13, 2008
- Lantus + Apidra Combination Therapy Effective for Diabetics
October 13, 2008
- Sales Force Effectiveness Japan 2008 Conference: eyeforpharma
October 13, 2008
- R&D NEWS IN BRIEF
October 13, 2008
- Kowa Trains Managers on How to Coach MRs during Customer Visits
October 13, 2008
- 16th JBCS Annual Meeting
October 13, 2008
- Biosimilars Should Reduce Healthcare Costs to Be Generally Accepted
October 13, 2008
- DDS Development Key to AMD
October 13, 2008
- Will Distribution Practices Be Improved? Part 5 (Final)
October 13, 2008
- Lantus Lowers HbA1C and Is Cost-Effective: sanofi-aventis
October 13, 2008
- BUSINESS NEWS IN BRIEF
October 13, 2008
- Heart Failure Can Be Prevented by Controlling BP: Prof. Komuro
October 13, 2008
- Takeda Applies for Alogliptin without Conducting PIII in Japan
October 13, 2008
- Prevention of Locomotor Disorders Urgently Required: JOA
October 13, 2008
- Korosho to Survey Code Labeling of Drugs
October 13, 2008
- 97% of Hospitals Protect ED Patient Privacy: Lilly Survey
October 13, 2008
- Companies Must More Quickly Decide Development to Eliminate Drug Lag: Mr Sato
October 13, 2008
- Change Mindset from Treatment to Prevention: Dr R.H. Carmona
October 13, 2008
- NCVC to Switch Top 150 Original Drugs to Generics
October 13, 2008
- Bayer to Expand Women's Healthcare Business
October 13, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…